Barrier-penetrating liposome targeted delivery of basic fibroblast growth factor for spinal cord injury repair.

Autor: Wu F; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China.; Translational Medicine Laboratory, Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, 325300, China.; School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, 325035, China., Wang P; Translational Medicine Laboratory, Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, 325300, China., Wei X; Translational Medicine Laboratory, Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, 325300, China., Yang Y; School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, 325035, China., Al Mamun A; School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, 325035, China., Zhang X; Department of Pharmacy, Ningbo Medical Treatment Center Li Huili Hospital, Zhejiang, 315040, China., Zhu Y; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China., Mo T; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China., Zhang H; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China.; Translational Medicine Laboratory, Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, 325300, China.; School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, 325035, China., Jiang C; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China., Hu J; Stem Cell Translation Laboratory, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Shanxi, 030032, China., Xiao J; Department of Arthroplasty, The First People's Hospital of Wenling, Affiliated Wenling Hospital, Wenzhou Medical University, Zhejiang, 317500, China.; Translational Medicine Laboratory, Affiliated Cixi Hospital, Wenzhou Medical University, Zhejiang, 325300, China.; School of Pharmaceutical Sciences, Wenzhou Medical University, Zhejiang, 325035, China.
Jazyk: angličtina
Zdroj: Materials today. Bio [Mater Today Bio] 2023 Jan 07; Vol. 18, pp. 100546. Date of Electronic Publication: 2023 Jan 07 (Print Publication: 2023).
DOI: 10.1016/j.mtbio.2023.100546
Abstrakt: Nanoparticle technologies offer a non-invasive means to deliver basic fibroblast growth factor (bFGF) for the treatment of spinal cord injury (SCI). However, the inability of bFGF to accumulate at the injury site and inefficient penetration across the blood-spinal cord barrier (BSCB) remain challenges. The present study describes a dual-targeting liposome (bFGF@Lip-Cp&Rp) with injury lesion targeting and BSCB-penetrating capability to deliver bFGF for SCI treatment. The CAQK peptide (Cp) with injury lesion targeting ability and R 2 KC peptide (Rp) with BSCB-penetrating capability were grafted onto the liposomes for a flexible and non-invasive drug delivery systems preparation. Results exhibit that the dual-targeted liposomes could significantly cross the BSCB and accumulate at the injury site. During the early stage of SCI, bFGF@Lip-Cp&Rp promotes repair of BSCB and facilitates M2-polarization of macrophages. Regular delivery of bFGF@Lip-Cp&Rp increase HUVECs tube formation and angiogenesis, ameliorate the microenvironment of lesion site, suppress the neuronal apoptosis and axonal atrophy in SCI rats. Importantly, continuous treatment of bFGF@Lip-Cp&Rp supports the restoration of limb motor function in SCI rats. In summary, this research implies that the injury site-targeting and BSCB-penetrating liposomes could be a promising therapeutic approach for the treatment of SCI.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2023 The Authors.)
Databáze: MEDLINE
Externí odkaz: